Although case of cytokine release syndrome occurring 5 days after BTN162b2 mRNA COVID-19 vaccination in patient with long-term anti-PD-1 therapy have been reported (168), the benefit-risk profile still strongly supports vaccination in cancer patients. Here, PDCD1 is linked to cancer.